Evolent Health (EVH) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Evolent Health (NYSE: EVH):

• 7/23/2026 – Evolent Health was downgraded by Citigroup Inc. from “buy” to “sell”.
• 7/23/2026 – Evolent Health had its “sell” rating reaffirmed by Citigroup Inc.. They now have a $6.75 price target on the stock, up from $5.50.
• 7/21/2026 – Evolent Health had its price target raised by Canaccord Genuity Group Inc. from $6.00 to $7.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Evolent Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/30/2026 – Evolent Health was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $7.00 price target on the stock.
• 6/24/2026 – Evolent Health had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 6/12/2026 – Evolent Health had its price target raised by Truist Financial Corporation from $6.00 to $7.00. They now have a “buy” rating on the stock.

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.